HC Wainwright Forecasts Lipocine’s Q1 Earnings (NASDAQ:LPCN)

Lipocine Inc. (NASDAQ:LPCN) – Research analysts at HC Wainwright upped their Q1 2026 earnings per share (EPS) estimates for shares of Lipocine in a report released on Monday, March 30th. HC Wainwright analyst Y. Chen now expects that the specialty pharmaceutical company will post earnings of ($0.51) per share for the quarter, up from their previous estimate of ($0.60). HC Wainwright has a “Neutral” rating on the stock. HC Wainwright also issued estimates for Lipocine’s Q2 2026 earnings at ($0.47) EPS, Q3 2026 earnings at ($0.47) EPS, Q4 2026 earnings at ($0.47) EPS and FY2026 earnings at ($1.91) EPS.

Lipocine (NASDAQ:LPCN) last released its earnings results on Tuesday, March 10th. The specialty pharmaceutical company reported ($0.34) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.60) by $0.26. Lipocine had a negative return on equity of 59.30% and a negative net margin of 487.00%.The company had revenue of $1.15 million for the quarter, compared to analysts’ expectations of $0.12 million.

Several other equities analysts have also recently issued reports on the company. Wall Street Zen upgraded Lipocine from a “sell” rating to a “hold” rating in a research report on Sunday, March 22nd. Weiss Ratings reissued a “sell (d-)” rating on shares of Lipocine in a research note on Friday, March 27th. One analyst has rated the stock with a Strong Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $15.00.

Lipocine Trading Up 3.1%

NASDAQ LPCN opened at $2.00 on Tuesday. The business’s 50 day moving average is $7.93 and its two-hundred day moving average is $5.77. Lipocine has a 12-month low of $1.81 and a 12-month high of $12.37. The stock has a market capitalization of $14.60 million, a price-to-earnings ratio of -1.19 and a beta of 1.09.

Institutional Investors Weigh In On Lipocine

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Renaissance Technologies LLC lifted its stake in Lipocine by 3.6% in the 4th quarter. Renaissance Technologies LLC now owns 37,397 shares of the specialty pharmaceutical company’s stock valued at $300,000 after buying an additional 1,300 shares in the last quarter. Geode Capital Management LLC lifted its stake in Lipocine by 2.2% in the 4th quarter. Geode Capital Management LLC now owns 62,450 shares of the specialty pharmaceutical company’s stock valued at $502,000 after buying an additional 1,374 shares in the last quarter. Jane Street Group LLC purchased a new stake in Lipocine in the 4th quarter valued at approximately $85,000. Citadel Advisors LLC purchased a new stake in Lipocine in the 3rd quarter valued at approximately $41,000. Finally, Boothbay Fund Management LLC purchased a new stake in Lipocine in the 4th quarter valued at approximately $441,000. Hedge funds and other institutional investors own 9.11% of the company’s stock.

Insider Activity at Lipocine

In related news, Director John W. Higuchi bought 40,000 shares of Lipocine stock in a transaction that occurred on Tuesday, April 7th. The shares were purchased at an average price of $2.03 per share, with a total value of $81,200.00. Following the purchase, the director owned 203,797 shares in the company, valued at $413,707.91. This represents a 24.42% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Mahesh V. Patel bought 25,000 shares of Lipocine stock in a transaction that occurred on Monday, April 6th. The stock was bought at an average cost of $2.03 per share, for a total transaction of $50,750.00. Following the purchase, the chief executive officer owned 160,679 shares in the company, valued at $326,178.37. This represents a 18.43% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have bought a total of 213,000 shares of company stock worth $434,600 in the last three months. Corporate insiders own 6.35% of the company’s stock.

More Lipocine News

Here are the key news stories impacting Lipocine this week:

• Positive Sentiment: Company insiders increased stakes — CEO Mahesh Patel bought 25,000 shares (~$2.03 avg) and director John W. Higuchi bought 123,000 shares, signaling insider confidence and providing buy-side support to the stock. Mahesh Patel Purchases 25,000 Shares of Lipocine (NASDAQ:LPCN) Stock
• Neutral Sentiment: HC Wainwright updated models upward — the firm raised FY2026 and quarterly EPS forecasts (e.g., FY2026 to ($1.91) from ($2.27) and several quarter EPS revisions) but keeps a “Neutral” rating, an outcome that reduces downside in estimates but does not convert to an upgrade. MarketBeat summary of analyst estimates
• Neutral Sentiment: Recent quarterly results showed a revenue beat and narrower-than-expected EPS loss (reported ($0.34) vs consensus ($0.60)), which supports the revised analyst estimates but the company remains loss-making and small-cap volatility is high. MarketBeat financial summary
• Negative Sentiment: HC Wainwright appears to have reduced its stance in a separate report (MSN coverage) — any downgrade or more cautious wording from a specialist biotech/healthcare desk can prompt short-term selling in a low-float name like LPCN. HC Wainwright & Co. downgrades Lipocine (LPCN)
• Negative Sentiment: Shareholder litigation inquiry — Johnson Fistel announced an investigation into potential claims involving Lipocine executives; legal risk and potential costs can weigh on sentiment and valuation. Johnson Fistel investigation announcement

Lipocine Company Profile

Lipocine Inc is a clinical-stage pharmaceutical company focused on the development and commercialization of oral drug delivery technologies. The company’s core expertise lies in lipid-based formulations designed to improve the bioavailability of therapeutics that traditionally require injectable administration. By leveraging proprietary technologies, Lipocine aims to offer patient-friendly alternatives with the potential for more consistent pharmacokinetic profiles and improved compliance.

The company’s lead product, TLANDO (LPCN 1021), is an oral testosterone replacement therapy approved by the U.S.